CD19/BCMA Chimeric Antigen Receptor T Cells Therapy
A chimeric antigen receptor (CAR) is a cellular receptor engineered to connect an extracellular targeting function with intracellular domains that activate the cytotoxic potential of T cells. CAR (Chimeric Antigen Receptor) T cells are T cells that have been engineered with additional receptors to identify specific proteins, called antigens, present on the surface of other cells. The Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach is designed to transiently, but fully, eliminate B cells, thus potentially enabling an “immune system reset.” CD19/BCMA CAR-T cells are novel CAR-T cells that are designed to deplete B cells.
Enroll in this clinical study
How is CD19/BCMA Chimeric Antigen Receptor T Cells being studied in Lupus nephritis?
The safety and effectiveness of CD19/BCMA CAR-T cells in the treatment of refractory systemic lupus erythematosus are being explored in this study. The primary outcome is the dose-limiting toxicity and Incidence of treatment-emergent adverse events.
Eligibility Criteria
Immune Nephritis with positive CD19/BCMA expression, and the conventional treatment is not effective and (or) no effective treatment
Estimated survival time> 12 weeks